James Rolke

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA.

Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA.

Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA.

GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA.

Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA.

Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA.

Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million.